Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... inhibitors. Indeed, the first complement inhibitor eculizumab , a humanized anti-C5 monoclonal antibody , has been ... for the treatment of PNH patients. Chronic treatment with eculizumab results in sustained control of intravascular hemolysis, leading to ...

    Research Article last updated 10/02/2012 - 9:57am.

  2. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria

    ... and CD59 on affected erythrocytes. The anti-C5 antibody eculizumab has proven clinically effective, but uncontrolled C3 activation ...

    Research Article last updated 03/06/2014 - 11:17am.

  3. Patrizia Ricci, PhD

    ... . Recently, the availability of the complement inhibitor eculizumab has dramatically improved the treatment of PNH. Nevertheless, about half of the patients treated with eculizumab shows a persistence of clinical signs of the disease. We have ...

    Grant Recipient last updated 09/14/2016 - 2:42pm.

  4. Long-term outcome of fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria

    ... option for PNH patients who are not candidates for eculizumab treatment. Bone Marrow Diseases:  ...

    Research Article last updated 06/02/2014 - 11:39am.

  5. Chao-Yie Yang, MD, PhD

    ... . Current FDA-approved only treatment for PNH is eculizumab which is expensive, unable to eradicate PNH clone , not ... in PNH. Current only FDA-approved treatment for PNH is eculizumab which is expensive, unable to eradicate PNH clone , not ...

    Grant Recipient last updated 08/09/2016 - 1:02pm.

  6. Thrombosis in paroxysmal nocturnal hemoglobinuria.

    ... and endothelial dysfunction. Complement inhibition with eculizumab generally has a dramatic effect in PNH and has a major impact in ...

    Research Article last updated 05/14/2013 - 3:29pm.

  7. A closer look at paroxysmal nocturnal hemoglobinuria

    ... development of the novel targeted therapeutic agent eculizumab has offered new promises for this highly morbid and fatal ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.

    ... specific interventions with anticoagulation and/or eculizumab . Of the 7 patients who did require therapy for clinical ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).

    ... targeting the terminal complement protein C5 ( Eculizumab ), anticoagulation, and in some cases allogeneic HSC transplant. ...

    Research Article last updated 10/22/2013 - 3:44pm.

  10. Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria

    ... One patient, who had had only a partial response to eculizumab , responded to SSAE not only with an improved platelet count, ... red cells in patients who have had a limited response to eculizumab, resulting in an improved quality of life for selected patients. ...

    Research Article last updated 04/17/2014 - 1:34pm.